TherapeuticsMD (TXMD) Cash & Equivalents (2010 - 2026)

TherapeuticsMD's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $8.4 million for Q1 2026.

• Quarterly Cash & Equivalents rose 46.54% year-over-year to $8.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.4 million (up 46.54% YoY) and the FY2025 annual result came in at $7.5 million, up 47.91% from the prior year.
• Cash & Equivalents was $8.4 million for Q1 2026 at TherapeuticsMD, up from $7.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $49.3 million in Q4 2022 and bottomed at $4.3 million in Q4 2023.
• A 5-year average of $15.0 million and a median of $7.5 million in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents tumbled 91.23% — and 2025, when it surged 47.91%.
• TherapeuticsMD's Cash & Equivalents stood at $49.3 million in 2022, then tumbled by 91.23% to $4.3 million in 2023, then climbed by 16.92% to $5.1 million in 2024, then jumped by 47.91% to $7.5 million in 2025, then advanced by 12.51% to $8.4 million in 2026.
• Business Quant data shows TXMD's Cash & Equivalents at $8.4 million in Q1 2026, $7.5 million in Q4 2025, and $7.1 million in Q3 2025.